Latest News
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
New technology has potential to accelerate timelines for therapeutic research and drug development SAN DIEGO–(BUSINESS WIRE)–May 28, 2025– Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated…
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis
SAN DIEGO–(BUSINESS WIRE)–Mar. 18, 2025– Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement…
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) — A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable…
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in…
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today…
Telesis Bio Reports First Quarter 2024 Financial Results
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced…
Telesis Bio Announces Reverse Stock Split
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) — Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab,…
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the commercial availability of its groundbreaking Gibson SOLA platform.…
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced…
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Telesis Bio announces Q4 and full-year 2023 select preliminary financial results, highlighting strong BioXp kit sales, expanding gross margin and reduced expense SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA…